Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B

Trial Profile

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vebicorvir (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Assembly Biosciences

Most Recent Events

  • 26 Jun 2022 Results assessing clinical evaluation of VBR 's drug-drug interaction (DDI) potential from Phase 1 (Study 103 ) and Phase 2a (NCT03577171, NCT03576066) studies, presented at The International Liver Congress 2022.
  • 08 Jun 2022 According to an Assembly Biosciences media release, data from this study will be presented at the International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver (EASL).
  • 20 Apr 2022 Results published in the Journal of Hepatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top